Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS continued 16.
INVESTMENTS IN ASSOCIATES AND JOINT VENTURES A loss of $6 million 2013: $3 million, representing the Groups share of the result of Unimark Remedies Limited and Hubei Haosun Pharmaceutical Co. Ltd, is included in the consolidated income statement.
For the year ended 31 December 2014 For the year ended 31 December 2013 Joint Joint ventures Associates Total ventures Associates Total $m $m $m $m $m $m Balance at 1 January 3 19 22 38 38 Additions 3 3 Share of loss 6 6 3 3 Impairment of investment as explained in Note 5 16 16 Balance at 31 December 3 13 16 3 19 22 Summarised financial information in respect of the Groups interests in associated companies is set out below: For the year For the year ended ended 31 December 31 December 2014 2013 $m $m Total assets 220 226 Total liabilities 148 141 Net assets 72 85 Group's share of net assets of associates 17 20 Total revenues 50 106 Net loss 27 14 Group's share of loss of associates 6 3 17.
DEFERRED TAX The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior reporting year: Other short-term Deferred temporary Amortisable Fixed Share-based Tax losses R&D costs differences assets assets payments Total $m $m $m $m $m $m $m At 1 January 2013 1 49 19 9 1 23 Credit to income 40 1 41 Acquisition of subsidiaries 4 4 At 1 January 2014 1 89 22 9 1 60 Charge Credit to income 4 12 1 7 Acquisition of business 13 13 Exchange differences 2 2 At 31 December 2014 4 1 77 20 22 2 42 Certain deferred tax assets and liabilities have been appropriately offset.
The following is the analysis of the deferred tax balances after offset for financial reporting purposes: As at 31 December 2014 2013 $m $m Deferred tax liabilities 25 26 Deferred tax assets 67 86 42 60 146
